• AZ’s Fasenra stumbles in P3 for COPD pharmafile
    May 15, 2018
    AstraZeneca’s Fasenra arrived later on the scene than GSK rival med, Nucala, and so it needed to quickly rack up indications to mount a serious challenge – in COPD,
PharmaSources Customer Service